In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report), ...
It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...
Trump administrations pro-corporation policies boost healthcare M&A prospects Healthcare investment outlook improves as Trump ...
Roche's GLP-1 drug candidates, acquired from Carmot Therapeutics, are crucial for its valuation, with promising early-stage results but some concerning side effects. The Poseida deal, though ...
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. Poseida’s pipeline includes ...
Poseida Therapeutics, Inc. (NASDAQ:PSTX), a biotechnology company specializing in biological products with a market capitalization of $929 million, announced today that it has completed a significant ...
Hosted on MSN15d
European stocks mostly lower; German data points to weak economyInvesting.com - European stock markets closed mostly down Wednesday, with investors fretting following the release of ...
Inc.'s subsidiary Blue Giant Acquisition Corp. has successfully completed a tender offer for all outstanding shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX). Roche's offer included $9.00 per share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback